开设账户
模拟账户
关于我们
即时报价及新闻
市场分析
财经日历
每日市场分析
交易平台
下载及介绍
使用教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
繁
简
EN
客户登入
开设账户
模拟账户
繁
简
EN
客户登入
开设账户
模拟账户
关于我们
上志国际介绍
上志国际优势
即时报价及新闻
即时报价
即时新闻
市场分析
财经日历
市场分析
交易平台
平台特点
平台教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
关于我们
交易细则
贵金属市场
交易平台
市场分析
推广和资讯
常见问题
联络我们
繁
简
EN
据国际文传电讯社:俄罗斯石油巨头Tatneft已在俄罗斯境内的所有加油站实施燃油销售限制。
2026-06-16
据国际文传电讯社:俄罗斯石油巨头Tatneft已在俄罗斯境内的所有加油站实施燃油销售限制。
返回
其他消息
2026-06-16
The U.S. and Iran are preparing to formally sign a temporary peace agreement in Switzerland on Friday; both sides claim victory. Oil traders and shippers remain uncertain how quickly navigation through the Strait of Hormuz will resume. Trump is attending the G7 summit in France, and G7 members are expected to play a central role in any mine‑clearing operations to restore shipping. A G7 official said Italy’s defense minister Crosetto met U.S. defense secretary Hegseth in Washington on Monday to d
The U.S. and Iran are preparing to formally sign a temporary peace agreement in Switzerland on Friday; both sides claim victory. Oil traders and shippers remain uncertain how quickly navigation through the Strait of Hormuz will resume. Trump is attending the G7 summit in France, and G7 members are expected to play a central role in any mine‑clearing operations to restore shipping. A G7 official said Italy’s defense minister Crosetto met U.S. defense secretary Hegseth in Washington on Monday to discuss an Italian task group of four vessels for the Strait, including two minehunters currently deployed to Djibouti and being readied for the mission.
2026-06-16
JP Morgan upgraded Hengrui Medicine (01276.HK) from Hold to Overweight and trimmed its target price to HK$68 from HK$70. The bank said the sharp share-price decline reflects macro headwinds—notably heightened U.S.-China geopolitical tensions and broad institutional de-risking of H-share healthcare—rather than a material weakening of fundamentals. At current levels, JP Morgan sees valuation as understating an improving earnings trajectory, rapidly expanding pipeline value and BD-related revenue,
JP Morgan upgraded Hengrui Medicine (01276.HK) from Hold to Overweight and trimmed its target price to HK$68 from HK$70. The bank said the sharp share-price decline reflects macro headwinds—notably heightened U.S.-China geopolitical tensions and broad institutional de-risking of H-share healthcare—rather than a material weakening of fundamentals. At current levels, JP Morgan sees valuation as understating an improving earnings trajectory, rapidly expanding pipeline value and BD-related revenue, but warned U.S. rules could constrain future China-origin licensing deals and increase volatility.
Chat with us
, powered by
LiveChat